Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir plus Lamivudine switch in transgender women with HIV
NCT06967753Phase 4Recruiting
- Sponsor
- UBATEC
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir and lamivudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by UBATEC. Primary endpoint: Virological efficacy at 48 weeks. Started Jul 2025; status: recruiting.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06967753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967753.